5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivates thereof
View Patent ↗Compositions comprising 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivatives thereof for the treatment of depression are disclosed.
1. A pharmaceutical composition comprising an MT-3 agonist of the following formula I:
wherein
R is —S(O) 2 R 1 or S(O)R 1 ,
R 1 is optionally substituted alkyl; optionally substituted alkoxy; optionally substituted aminoalkyl; optionally substituted carbocyclic aryl; an optionally substituted alkylaryl;
R 2 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aminoalkyl; and pharmaceutically acceptable salts thereof,
R 3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl; and pharmaceutically acceptable salts thereof,
wherein the optional substituents, which may be at one or more available positions, are selected from the group consisting of halogen, cyano, hydroxyl, nitro, azido, C 1-6 alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl and aminoalkyl
with the proviso that when R 1 is methyl, R 2 cannot be iodine or bromine and when R 1 is methyl, R 2 and R 3 cannot both be hydrogen and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , further comprising a Ca ++ antagonist.
3. The pharmaceutical composition of claim 2 , wherein the Ca ++ antagonist is nifedipine.
4. The pharmaceutical composition of claim 3 further comprising an acceptable carrier.
5. The pharmaceutical composition of claim 1 , wherein R 1 is optionally substituted C 1-6 alkyl or optionally substituted C 1-6 alkoxy.
6. The pharmaceutical composition of claim 1 , wherein R 2 and R 3 are each independently halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, or optionally substituted C 1-6 alkythio.
7. The pharmaceutical composition of claim 1 further comprising an acceptable carrier.